Advances in the development of new biologics in inflammatory bowel disease

Δείτε το αρχείο http://www.annalsgastro.gr/index.php/annalsgastro/article/view/2591  
Φορέας Ελληνική Γαστροεντερολογική Εταιρία
Συλλογή Annals of Gastroenterology Advances in the development of new
biologics in inflammatory bowel disease
Επιμέρους συλλογή Invited Review
ΠεριγραφήBiologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infl iximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.Keywords Infl ammatory bowel disease, Crohn’s disease, ulcerative colitis, therapy, biologicsAnn Gastroenterol 2016; 29 (3): 243-248
Δημιουργοί Ungar, Bella Kopylov, Uri
ΕκδότηςAnnals of Gastroenterology
Ημερομηνία2016-06-29
Μορφότυπος"application/pdf"
Μορφότυποςtext/html
ΠηγήAnnals of Gastroenterology; Volume 29, No 3 (2016); 243